Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
1,576
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience

Luigi Gargiuloa Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy;b Department of Biomedical Sciences, Humanitas University, Milan, ItalyView further author information
,
Luciano Ibbaa Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy;b Department of Biomedical Sciences, Humanitas University, Milan, ItalyCorrespondence[email protected]
View further author information
,
Carlo A. Vignolia Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy;b Department of Biomedical Sciences, Humanitas University, Milan, ItalyView further author information
,
Silvia M. Ferruccic Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyView further author information
,
Santo R. Mercurid Dermatology and Cosmetology Unit, IRCCS San Raffaele Hospital, Milan, ItalyView further author information
,
Piergiorgio Malagolie Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, ItalyView further author information
,
Angelo V. Marzanoc Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy;f Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, ItalyView further author information
,
Mauro Barbareschif Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, ItalyView further author information
,
Vittoria G. Bianchid Dermatology and Cosmetology Unit, IRCCS San Raffaele Hospital, Milan, ItalyView further author information
,
Mario Valentia Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy;b Department of Biomedical Sciences, Humanitas University, Milan, ItalyView further author information
,
Antonio Costanzoa Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy;b Department of Biomedical Sciences, Humanitas University, Milan, ItalyView further author information
&
Alessandra Narcisia Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, ItalyView further author information
 show all
Article: 2268764 | Received 04 Oct 2023, Accepted 04 Oct 2023, Published online: 11 Oct 2023

References

  • Pratt CH, King LEJr, Messenger AG, et al. Alopecia areata. Nat Rev Dis Primers. 2017;3(1):1. doi: 10.1038/nrdp.2017.11.
  • Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol. 2018;79(3):556.e1–3. doi: 10.1016/j.jaad.2018.01.048.
  • Meah N, Wall D, York K, et al. The alopecia areata consensus of experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83(1):123–130. doi: 10.1016/j.jaad.2020.03.004.
  • Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–1049. doi: 10.1038/nm.3645.
  • King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687–1699. doi: 10.1056/NEJMoa2110343.
  • Kwon O, Senna MM, Sinclair R, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443–451. doi: 10.1007/s40257-023-00764-w.
  • Freitas E, Guttman-Yassky E, Torres T. Baricitinib for the treatment of alopecia areata. Drugs. 2023;83(9):761–770. doi: 10.1007/s40265-023-01873-w.
  • Gargiulo L, Ibba L, Piscazzi F, et al. Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: a 52-week retrospective study. J Eur Acad Dermatol Venereol. 2023 [published online ahead of print, 2023 Sep 15]. doi: 10.1111/jdv.19507.
  • Vittrup I, Elberling J, Skov L, et al. Short-term real-world experience with baricitinib treatment in danish adults with moderate-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37(4):e543–e546. doi: 10.1111/jdv.18804.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.